Results 221 to 230 of about 2,215,729 (248)

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani, Tsuyoshi Nakai, Yasuhiro Maeda, Reiko Ohdake, Atsuhiro Higashi, Toshiki Maeda, Ryunosuke Nagao, Sayuri Shima, Kazuya Kawabata, Akihiro Ueda, Mizuki Ito, Hirohisa Watanabe   +11 more
wiley   +1 more source

Aβ and tau clearance through aerobic exercise: unveiling the β2-adrenergic receptor's role in regulating autophagy-lysosomal pathways. [PDF]

Autophagy Rep
Yang L, Yu H, Chai GS.
europepmc   +1 more source

Rôles des NADPH oxydases lors de pathologies humaines à l'aide de modèles murins transgéniques

, 2009
Christine Deffert, Bernard Lardy, Françoise Morel   +2 more
openalex   +1 more source

Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross‐Sectional Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Managing long COVID in people with multiple sclerosis and related disorders (pwMSRD) is complex due to overlapping symptoms. To address evidence gaps, we evaluated long COVID susceptibility in pwMSRD versus controls and its associations with multi‐domain function and disability.
Chen Hu, Jiyeon Son, Lindsay McAlpine, Elizabeth L. S. Walker, Megan Dahl, Emily Song, Sugeidy Ferreira Brito, Katelyn Kavak, Kaho Onomichi, Amit Bar‐Or, Christopher Perrone, Claire S. Riley, Bianca Weinstock‐Guttman, Philip L. De Jager, Erin E. Longbrake, Zongqi Xia   +15 more
wiley   +1 more source

Stage-specific roles of clonally expanded CD8⁺ T cells in regulating amyloid pathology in Alzheimer's disease models. [PDF]

Nat Commun
Ohyagi M, Ito M, Iizuka-Koga M, Mise-Omata S, Yoshimura A.   +4 more
europepmc   +1 more source

Plasma p‐tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Plasma p‐tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p‐tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Giulia Giacomucci, Assunta Ingannato, Chiara Crucitti, Silvia Bagnoli, Elisa Marcantelli, Sonia Padiglioni, Valentina Moschini, Carmen Morinelli, Laura Falsini, Sandro Sorbi, Valentina Berti, Benedetta Nacmias, Valentina Bessi   +12 more
wiley   +1 more source

APOE ε4 linked effects on clinical features and neuropathology in dementia with Lewy bodies. [PDF]

Alzheimers Dement
Ye R, Goodheart AE, Locascio JJ, Peterec EC, Stancu P, Wang Y, Gomperts SN.   +6 more
europepmc   +1 more source

Reply to Letter: “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

Annals of Clinical and Translational Neurology, EarlyView.
Yana Said, Eoin P. Flanagan, Elias S. Sotirchos   +2 more
wiley   +1 more source

Moyamoya Disease and the Risk of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by the progressive narrowing of arteries at the base of the brain, forming abnormal collateral vascular networks. While vascular parkinsonism is noted in MMD, its link to Parkinson's disease (PD) has not been explored.
Dallah Yoo, Jeong‐Yong Shin, Rugyeom Lee, Jiwon Cheon, Ji Hun Kim, Doeun Kim, Jae‐Kyung Won, In‐Hwan Oh, Yunjong Lee, Tae‐Beom Ahn   +9 more
wiley   +1 more source

Immunotherapy in Early Parkinson's Disease: A Biomarker-Driven Trial Framework for Secondary Prevention. [PDF]

Cureus
Kniazev R.
europepmc   +1 more source